[Table/Fig-3]:
Human vaccines in clinical trial.
| S. No. | Pharmaceutical Company |
Vaccine | Content | Status of Trial |
|---|---|---|---|---|
| 1 | GlaxoSmithKline (GSK) | cAd3-EBO | type chimpanzee adenovirus type 3 (ChAd3), as a carrier | Phase 1 |
| 2 | Public Health Agency of Canada with Merck | rVSV-ZEBOV | attenuated vesicular stomatitis virus | Phase 1 |
| 3 | Johnson and Johnson with company Bavarian Nordic | Ad26.ZEBOV/MVA-BN-Filo | replication-defective adenovirus-vector | Phase 1 |
| 4 | Novavax | EBOV GP Nanoparticle | Baculovirus- derived Ebola GP nanoparticle + Matrix M adjuvant | Phase 1 |
| 5 | NovaSep | rVSVN4CT1 EBOV (Profectus) | recombinant Ad5 virus--vector | Pre clinical trial |
| 6 | Niaid with IDT Biologika | Rabies EBOV-GP | vector based combination trivalent (Zaire, Sudan, Marburg) | Pre clinical trial |
| 7 | Lonza | VXA ZEBOV -GP (VaxArt) | recombinant VSV- vector vaccine | Pre clinical trial |